EVELO BIOSCIENCES INC's ticker is EVLO and the CUSIP is 299734103. A total of 43 filers reported holding EVELO BIOSCIENCES INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $44,000 | -55.6% | 12,930 | -20.9% | 0.00% | – |
Q4 2021 | $99,000 | -13.9% | 16,344 | 0.0% | 0.00% | – |
Q3 2021 | $115,000 | -80.0% | 16,344 | -61.0% | 0.00% | -100.0% |
Q2 2021 | $576,000 | +54.8% | 41,923 | +20.7% | 0.00% | – |
Q1 2021 | $372,000 | +1.6% | 34,735 | +14.8% | 0.00% | -100.0% |
Q4 2020 | $366,000 | +218.3% | 30,268 | +38.7% | 0.00% | – |
Q3 2020 | $115,000 | +7.5% | 21,824 | 0.0% | 0.00% | – |
Q2 2020 | $107,000 | +30.5% | 21,824 | 0.0% | 0.00% | – |
Q1 2020 | $82,000 | -6.8% | 21,824 | +1.1% | 0.00% | – |
Q4 2019 | $88,000 | -33.3% | 21,579 | 0.0% | 0.00% | – |
Q3 2019 | $132,000 | -32.0% | 21,579 | 0.0% | 0.00% | – |
Q2 2019 | $194,000 | +12.1% | 21,579 | 0.0% | 0.00% | – |
Q1 2019 | $173,000 | -38.4% | 21,579 | 0.0% | 0.00% | -100.0% |
Q4 2018 | $281,000 | +181.0% | 21,579 | +163.0% | 0.00% | – |
Q3 2018 | $100,000 | +3.1% | 8,206 | 0.0% | 0.00% | – |
Q2 2018 | $97,000 | – | 8,206 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Mayo Clinic | 484,953 | $1,823,000 | 4.61% |
Flagship Pioneering Inc. | 18,233,403 | $68,558,000 | 3.21% |
HARBOURVEST PARTNERS LLC | 1,763,505 | $6,622,000 | 3.20% |
Alphabet Inc. | 1,060,495 | $3,982,000 | 0.26% |
Larson Financial Group LLC | 20,042 | $75,000 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,500 | $501,000 | 0.01% |
CREDIT SUISSE AG/ | 1,500,117 | $5,633,000 | 0.01% |
FMR LLC | 3,220,853 | $12,094,000 | 0.00% |
VICTORY CAPITAL MANAGEMENT INC | 177,856 | $668,000 | 0.00% |
Legal & General Group Plc | 1,522 | $6,000 | 0.00% |